Abstract:BackgroundLarge-scale genetic screening using CRISPR-Cas9 technology has emerged as a powerful approach to uncover and validate gene functions. The ability to control the timing of genetic perturbation during CRISPR screens will facilitate precise dissection of dynamic and complex biological processes. Here, we report the optimization of a drug-inducible CRISPR-Cas9 system that allows high-throughput gene interrogation with a temporal control.ResultsWe designed multiple drug-inducible sgRNA expression vectors and measured their activities using an EGFP gene disruption assay in 11 human and mouse cell lines. The optimal design allows for a tight and inducible control of gene knockout in vitro, and in vivo during a seven-week-long experiment following hematopoietic reconstitution in mice. We next performed parallel genome-wide loss-of-function screens using the inducible and constitutive CRISPR-Cas9 systems. In proliferation-based dropout screens, these two approaches have similar performance in discriminating essential and nonessential genes. In a more challenging phenotypic assay that requires cytokine stimulation and cell staining, we observed similar sensitivity of the constitutive and drug-induced screening approaches in detecting known hits. Importantly, we demonstrate minimal leakiness of our inducible CRISPR screening platforms in the absence of chemical inducers in large-scale settings.ConclusionsIn this study, we have developed a drug-inducible CRISPR-Cas9 system that shows high cleavage efficiency upon induction but low background activity. Using this system, we have achieved inducible gene disruption in a wide range of cell types both in vitro and in vivo. For the first time, we present a systematic side-by-side comparison of constitutive and drug-inducible CRISPR-Cas9 platforms in large-scale functional screens. We demonstrate the tightness and efficiency of our drug-inducible CRISPR-Cas9 system in genome-wide pooled screening. Our design increases the versatility of CRISPR-based genetic screening and represents a significant upgrade on existing functional genomics toolbox.

Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening.

A general approach to identify cell-permeable and synthetic anti-CRISPR small molecules

Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells.

Modulating CRISPR/Cas9 genome-editing activity by small molecules

De novo design of potent CRISPR-Cas13 inhibitors

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

Aptamer Inhibitor Selection of SpyCas9 Through CE-SELEX

A Novel CRISPR Interference Effector Enabling Functional Gene Characterization with Synthetic Guide RNAs

Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing

Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing

Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.

Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening

Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

Specific Modulation of CRISPR Transcriptional Activators through RNA-Sensing Guide RNAs in Mammalian Cells and Zebrafish Embryos

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export

Structure‐guided Engineering of Thermodynamically Enhanced SaCas9 for Improved Gene Suppression

Screening DNA Aptamers That Control the DNA Cleavage, Homology-Directed Repair, and Transcriptional Regulation of the CRISPR-(d)Cas9 System.

Split Cas9, Not Hairs - Advancing the Therapeutic Index of CRISPR Technology

Disabling Cas9 by an anti-CRISPR DNA mimic

Structure-switchable branched inhibitors regulate the activity of CRISPR-Cas12a for nucleic acid diagnostics